Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer

Aim Biochemical markers, including microRNAs (miRs), may facilitate the diagnosis and prognosis of breast cancer. This study was aimed at assessing serum miR-155 expression in patients with breast cancer and receptors. Methods This case-control study was conducted on 36 patients with breast cancer and 36 healthy individuals. After RNA extraction from the patient's serum, cDNA was synthesized. The expression of miR-155 was measured using RT-qPCR. Demographic and histochemical data were extracted from patient documents. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software. Results The mean age of subjects in breast cancer and control groups was 47.64 ± 8.19 and 47.36 ± 7.52 years, respectively. The serum miR-155 expression was higher in the cancer group (1.68 ± 0.66) compared to the control group (p < 0.0001). There was a significant relationship between serum miR-155 expression and the tumor grade (p < 0.001), tumor stage (p < 0.001), and tumor size (p < 0.001) of the patients. However, no relationship between miR-155 expression and the presence of lymph node involvement (p = 0.15), HER2 (p = 0.79), Ki-67 (p = 0.9), progesterone receptor (p = 0.54), and estrogen receptors (p = 0.84) was found. The ROC curve analysis showed that the AUC was 0.89 (77.78% sensitivity and 88.89% specificity), and the cutoff was 1.4 (Youden index: 0.6667) for detecting breast cancer. Conclusion The findings of this study revealed that serum miR-155 may serve as a potential noninvasive molecular biomarker for breast cancer diagnosis and can help predict the grade of the disease.

[1]  A. Sahebkar,et al.  Evaluation of the Diagnostic Properties of Serum hsa-miR-223-5p in Detection of Gastric Cancer: A Case-Control Study. , 2020, Anti-cancer agents in medicinal chemistry.

[2]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[3]  R. Sarpong,et al.  Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02572c , 2019, Chemical science.

[4]  T. Stopka,et al.  Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer , 2017, International journal of molecular sciences.

[5]  J. Mohammadi-Asl,et al.  The Diagnostic Value of miR-155 Expression in the Serum of Patients with Breast Cancer According to Molecular Subtypes of Breast Cancer , 2017 .

[6]  D. Pang,et al.  A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer , 2017, Annals of surgical treatment and research.

[7]  S. Xie,et al.  Higher expression of circulating miR-182 as a novel biomarker for breast cancer , 2013, Oncology letters.

[8]  Cristina Rodríguez-Padilla,et al.  Serum Circulating microRNA Profiling for Identification of Potential Breast Cancer Biomarkers , 2013, Disease markers.

[9]  D. Jiao,et al.  miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. , 2012, Oncology letters.

[10]  Yu Sun,et al.  Serum MicroRNA-155 as a Potential Biomarker to Track Disease in Breast Cancer , 2012, PloS one.

[11]  Jingfeng Tang,et al.  Clinical significance of MicoRNA‐155 expression in human breast cancer , 2012, Journal of surgical oncology.

[12]  Wei Zhang,et al.  Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis , 2012, Oncology reports.

[13]  J. Hoeijmakers,et al.  MicroRNAs, the DNA damage response and cancer. , 2011, Mutation research.

[14]  Khadigeh Onsory,et al.  BREAST CANCER AND THE EFFECT OF ENVIRONMENTAL FACTORS INVOLVED , 2011 .

[15]  P. Salehian,et al.  Isolation of Mycobacterium Chelonae in the Sputum of Patient with Metastatic Breast Cancer , 2011 .

[16]  Shu Ichihara,et al.  Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.

[17]  M. Robson,et al.  American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. , 2010, Journal of Clinical Oncology.

[18]  N. Brünner,et al.  TIMP-1 as a tumor marker in breast cancer – An update , 2008, Acta oncologica.

[19]  G. Hortobagyi,et al.  Prognostic molecular markers in early breast cancer , 2004, Breast Cancer Research.

[20]  B. Jasani,et al.  Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries , 2000, Journal of clinical pathology.

[21]  J. R. Scott.  Danforth's Obstetrics and Gynecology , 1990 .

[22]  J. Bigby.  Harrison's Principles of Internal Medicine , 1988 .

[23]  Hua Yu,et al.  Diagnostic value of circulating miR-155 , miR-21 , and miR-10 b as promising biomarkers in human breast cancer , 2016 .

[24]  Jian Guo,et al.  Serum microRNA-155 in early diagnosis and prognosis of breast cancer , 2016 .

[25]  W. Marsden.  I and J , 2012 .

[26]  K. Offit,et al.  American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.